Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review - Takeaways - MDSpire

Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review

  • By

  • Fang, Yuang

  • Hu, Beilin

  • Mu, Guo

  • Yu, Hong

  • Zhou, Jun

  • April 6, 2026

  • 0 min

Share

  • 1

    Postoperative pain management in lower extremity joint arthroplasty often results in moderate-to-severe pain for two-thirds of patients within 24 hours.

  • 2

    Liposomal bupivacaine (LB) offers prolonged analgesia for up to 72 hours, addressing the limitations of conventional local anesthetics.

  • 3

    A systematic review of nine randomized controlled trials involving 828 patients found LB reduced 24-hour opioid requirements by 35-50%.

  • 4

    LB also resulted in a reduced hospital length of stay by an average of 0.5 days and improved early-phase analgesia.

  • 5

    The cost-effectiveness of LB varies by surgical procedure, and no significant analgesic difference was noted beyond 72 hours compared to controls.

Original Source(s)

Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review

  • by Fang, Yuang , Hu, Beilin , Mu, Guo , Yu, Hong , Zhou, Jun

  • April 6, 2026

Related Content

Preoperative oral spicy stimulation for postoperative pain reduction after spinal surgery: a randomized controlled trial

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

Not All Hips Follow the Same Rules in THA

Dynamic modeling suggested flatback deformity lowered target combined anteversion, while stiff pelvic mobility narrowed the acceptable range